PYZCHIVA

Drug Overview

PYZCHIVA (ustekinumab-ttwe) is a high-affinity, fully human MONOCLONAL ANTIBODY and a newly approved BIOSIMILAR within the IMMUNOLOGY drug category. It is classified as an INTERLEUKIN-12 (IL-12) AND INTERLEUKIN-23 (IL-23) INHIBITOR. As a TARGETED THERAPY, Pyzchiva serves as a clinically equivalent alternative to the reference product (Stelara), specifically designed to manage chronic, immune-mediated inflammatory diseases of the gastrointestinal tract and skin.

• Generic Name: Ustekinumab-ttwe
• Brand Name: Pyzchiva
• Drug Class: IL-12/IL-23 Inhibitor; BIOLOGIC; IMMUNOMODULATOR
• Route of Administration: Intravenous (IV) Infusion (Induction) and Subcutaneous (SC) Injection (Maintenance)
• FDA Approval Status: FDA-approved (2024) for the treatment of adult patients with Crohn’s Disease and ULCERATIVE COLITIS, as well as pediatric and adult patients with Plaque Psoriasis and Psoriatic Arthritis.

As a BIOSIMILAR, Pyzchiva has demonstrated through rigorous analytical and clinical testing that there are no “clinically meaningful differences” in safety, purity, or potency compared to its reference biologic. It is a critical component of modern INFLAMMATORY BOWEL DISEASE (IBD) management.

What Is It and How Does It Work? (Mechanism of Action)

Pyzchiva functions through SELECTIVE CYTOKINE INHIBITION, specifically targeting the p40 subunit shared by two pro-inflammatory cytokines: IL-12 and IL-23.

Molecular and Cellular Level Action

The drug interrupts the inflammatory signaling that leads to gut tissue damage:

1. p40 Binding: Pyzchiva binds with high specificity to the p40 protein subunit of the IL-12 and IL-23 cytokines.
2. Receptor Blockade: By binding these cytokines, the drug prevents them from attaching to the IL-12Rβ1 receptor on the surface of immune cells (such as T-cells and Natural Killer cells).
3. Pathway Interruption: This blockade prevents the signaling that normally triggers the activation and expansion of Th1 and Th17 cells.
4. Reduction of Inflammation: By silencing these pathways, Pyzchiva reduces the secretion of downstream inflammatory markers like TNF-alpha and Interferon-gamma, which are responsible for the ulceration and swelling in the intestinal lining.

FDA-Approved Clinical Indications

Primary Indication: Crohn’s Disease and Ulcerative Colitis

Pyzchiva is a potent IMMUNOMODULATOR for:

• Crohn’s Disease (CD): For adult patients with moderately to severely active CD who have failed or were intolerant to conventional therapy or TNF blockers.
• Ulcerative Colitis (UC): For adult patients with moderately to severely active UC.

Other Approved Uses

• Plaque Psoriasis: For adult and pediatric patients (6 years and older) with moderate-to-severe disease.
• Psoriatic Arthritis (PsA): For adult patients with active PsA to improve joint symptoms.

Primary Immunology Indications

• Mucosal Healing: Promoting the repair of the intestinal lining to prevent systemic damage such as fistulas or strictures.
• Selective Suppression: Targeting the specific IL-12/23 pathway rather than broadly suppressing the entire immune system.

Dosage and Administration Protocols

Pyzchiva utilizes a “Dual-Route” protocol for IBD to ensure rapid control followed by long-term maintenance.

Dose Adjustments and Special Populations

• The 8-Week Window: The first subcutaneous (SC) maintenance dose is administered 8 weeks after the initial IV infusion.
• Psoriasis Dosing: Unlike IBD, Psoriasis treatment is exclusively subcutaneous (45mg or 90mg based on weight) and typically administered every 12 weeks.
• Pediatric Use: While approved for pediatric psoriasis, IBD approval for Pyzchiva currently focuses on the adult population.

Clinical Efficacy and Research Results

Biosimilarity was confirmed through exhaustive clinical trials (2022–2024), showing identical efficacy to the reference product.

Numerical Research Data

• Clinical Remission (IBD): In pivotal trials, approximately 34% to 53% of Crohn’s patients achieved clinical remission following the initial IV induction.
• Durability: Data through 2026 shows that over 60% of patients who responded to induction remained in remission at the one-year mark with maintenance therapy.
• Switching Studies: Research has confirmed that patients can safely “switch” from the reference biologic to Pyzchiva without any loss of efficacy or increase in side effects.

Recent Research (2024–2026)

Current research in PRECISION IMMUNOLOGY is focusing on the “Anti-Drug Antibody” (ADA) profile of Pyzchiva. 2025 studies indicate that ADA formation is very low (less than 5%), which contributes to the long-term durability of the drug. Additionally, research into “Early Intervention” suggests that using Pyzchiva earlier in the disease course of Crohn’s leads to significantly better long-term mucosal healing outcomes.

Safety Profile and Side Effects

While Pyzchiva is a TARGETED THERAPY, it requires screening for potential infections.

Common Side Effects (>10%)

• Nasopharyngitis: Common cold symptoms.
• Headache: Usually mild and transient.
• Fatigue: Reported by many patients following the induction dose.
• Injection Site Reactions: Redness or swelling at the site of the SC shot.

Serious Adverse Events

• Serious Infections: Increased risk of bacterial, fungal, or viral infections (including Tuberculosis).
• Malignancies: A theoretical increased risk of non-melanoma skin cancer.
• Posterior Reversible Encephalopathy Syndrome (PRES): A very rare but serious brain condition involving headache, seizures, or vision changes.
• Non-Infectious Pneumonia: Rare instances of lung inflammation.

Management Strategies

• TB Screening: Mandatory QuantiFERON-TB Gold or skin test before starting therapy.
• Vigilance: Patients must be monitored for signs of infection or unusual neurological symptoms (PRES warning).

Research Areas

Direct Clinical Connections

Active research is exploring the drug’s role in the Gut-Skin Axis. Because IL-23 is a major driver of both Crohn’s and Psoriasis, Pyzchiva is uniquely positioned for patients who suffer from both conditions simultaneously.

Generalization and Advancements

• Novel Delivery: Development of high-concentration autoinjectors to reduce injection volume and pain.
• Precision Immunology: Using fecal calprotectin and serum drug levels to guide “Dose Intensification” for patients who show a partial response to the 8-week cycle.
• Combination Biologics: 2026 trials are investigating the safety of using Pyzchiva alongside other IMMUNOMODULATORS for “Refractory Crohn’s.”

Disclaimer: The research mentioned regarding the use of “trough level” therapeutic drug monitoring to guide dose intensification, the investigation of “combination biologic” protocols for refractory Crohn’s disease, and the use of serum drug levels as a biomarker to predict patient response is currently in the clinical/investigational phase or represents emerging practice and should be discussed with your specialist to determine its applicability to your individual care plan. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: CBC, LFTs, and baseline CRP/ESR.
• Infection Screening: Tuberculosis and Hepatitis B screening are required.
• Vaccination Check: Live vaccines (e.g., MMR, nasal flu) should not be given during treatment or for 15 weeks after the last dose.

Monitoring and Precautions

• Vigilance: Report any persistent cough, fevers, or unintended weight loss.
• Therapeutic Drug Monitoring: If symptoms flare, clinicians may check the “trough level” of the drug before the next dose.
• Lifestyle:
  • Skin Protection: Annual skin exams and daily SPF 50+ are recommended due to the potential skin cancer risk.
  • Adherence: Meticulous adherence to the 8-week schedule is necessary to prevent the development of antibodies.

Do’s and Don’ts

• DO store Pyzchiva in the refrigerator (2°C to 8°C) and protect it from light.
• DO allow the pre-filled syringe to reach room temperature for 30 minutes before injecting.
• DON’T use the medication if the liquid is cloudy or has floating particles.
• DON’T stop the medication just because you feel better; inflammation can return without the maintenance dose.

Legal Disclaimer

This guide is provided for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. The use of PYZCHIVA (ustekinumab-ttwe) must be managed by a qualified gastroenterologist or dermatologist. Always consult with your healthcare professional regarding the risks and benefits of BIOLOGIC therapy. Never disregard professional medical advice based on information provided in this guide.